| Identification | Back Directory | [Name]
AMifaMpridine Phosphate | [CAS]
446254-47-3 | [Synonyms]
6-DAP
3,6-DAP
BRN0110232
BRN-0110232
BRN 0110232
AMifaMpridine Phosphate
KAICRBBQCRKMPO-UHFFFAOYSA-N | [Molecular Formula]
C5H10N3O4P | [MDL Number]
MFCD28386276 | [MOL File]
446254-47-3.mol | [Molecular Weight]
207.124 |
| Hazard Information | Back Directory | [Uses]
Amifampridine (3,4-Diaminopyridine) phosphate is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB). Amifampridine phosphate is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine phosphate increases transmitter release from neuromuscular junctions (NMJs). Amifampridine phosphate can be used for Lambert-Eaton myasthenic syndrome (LEMS) research[1][2][3]. | [in vivo]
Amifampridine phosphate (Oral gavage; 10 mg/kg; once) can antagonize muscle paralysis following BoNT/A intoxication[2].
Amifampridine phosphate (2.5 mg/kg (IV); 10 mg/kg (PO); once) shows 1 hour plasma half-life and about 57% bioavailability (F) in mice[2].
Amifampridine phosphate has a short plasma half-life and can induce seizures when present at high concentrations, following penetration of the blood-brain barrier[2]. | Animal Model: | CD-1 mouse (female,25 g, 6 weeks old)[2] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage, once, after BoNT/A administration (IP) | | Result: | Revealed that neither LEMs alone (182 ± 43 min) nor the maximum safe orally deliverable dose of 3,4-DAP alone (225 ± 24 min) could significantly increase the time to death following toxin administration (216 ± 29 min). However, when the 10/50/40 3,4-DAP/LEM/shellac formulation was administered at 25 mg/kg the time to death was 302 ± 26 min - a 40% increase as compared to toxin alone. |
| Animal Model: | CD-1 mouse (30-35 g, 8 weeks old)[2] | | Dosage: | 2.5 mg/kg (IV); 10 mg/kg (PO) | | Administration: | IV, orally, once (Pharmacokinetic Analysis) | | Result: | Pharmacokinetic Parameters of Amifampridine in CD-1 mouse[1].
| IV (2.5 mg/kg) | PO (10 mg/kg) | | t1/2 (h) | 1.04 | 1.28 | | AUC0-24 (μM·h) | 4.29 | 9.72 | | F (%) | 100 | 56.7 |
|
| [References]
[1] Maarten J Titulaer, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10(12):1098-107. DOI:10.1016/S1474-4422(11)70245-9
[2] T L Harris, et al. Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. Chem Commun (Camb). 2016 Mar 18;52(22):4187-90. DOI:10.1039/c6cc00615a
[3] Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021 Jan-Jun;296:100302. DOI:10.1016/j.jbc.2021.100302 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|